All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for NOVO NORDISK INC. · Pharmaceutical company

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 3

CHRISTOPHER E. WILCOX

Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
JEANNE HAGGERTY

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
ROBERT BUTORA

Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 6509
SAFE Drugs Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 5

Health Issues

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794).

Budget/Appropriations

Support for obesity drug coverage and access.

Medicare/Medicaid

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Taxation/Internal Revenue Code

Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21.

General issues related to patent protections.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.